Colchicine Assessment of Low-grade Inflammation and Biomarker Response in Atherosclerosis with Targeted Evaluation

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525547-32-01

Enrollment

Registered

2026-05-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Coronary Artery Syndrome, Coronary Artery Disease, Ischemic Heart Disease

Brief summary

The primary endpoint is the change in arterial inflammation from baseline to 6 months, assessed by target-to-background ratio (TBR) of [¹⁸F]-FDG PET/CT in the carotid arteries.

Interventions

DRUGCOLCHICINE

DRUGPLACEBO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the change in arterial inflammation from baseline to 6 months, assessed by target-to-background ratio (TBR) of [¹⁸F]-FDG PET/CT in the carotid arteries.	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 7, 2026